



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>A01K 67/00</b>	<b>A2</b>	<b>(11) International Publication Number:</b> <b>WO 99/00010</b> <b>(43) International Publication Date:</b> 7 January 1999 (07.01.99)
<b>(21) International Application Number:</b> PCT/US98/13171 <b>(22) International Filing Date:</b> 25 June 1998 (25.06.98)  <b>(30) Priority Data:</b> 08/884,541 27 June 1997 (27.06.97) US  <b>(71) Applicant:</b> MEDAREX, INC. [US/US]; 1545 Route 22 East, P.O. Box 953, Annandale, NJ 08801-0953 (US).  <b>(72) Inventor:</b> VAN DE WINKEL, J., G., J.; Werdorperwaard 1A, NL-3984 PR Odijk (NL).  <b>(74) Agents:</b> REMILLARD, Jane, E. et al.; Lahive & Cockfield, LLP, 28 State Street, Boston, MA 02109 (US).		<b>(81) Designated States:</b> AU, CA, JP, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).  <b>Published</b> <i>Without international search report and to be republished upon receipt of that report.</i>
<b>(54) Title:</b> TRANSGENIC ANIMALS EXPRESSING HUMAN Fc RECEPTORS  <b>(57) Abstract</b>  Transgenic animals expressing Fc receptors and uses for the animals in testing the efficacy of human antibodies and in generating novel antibodies are described.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Larvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

5                   **TRANSGENIC ANIMALS EXPRESSING HUMAN Fc RECEPTORS****Background of the Invention**

Several types of effector cells, such as monocytes, neutrophils, and natural killer (NK) cells, have cell surface receptors that bind the Fc portion of immunoglobulins (Igs). When such cells encounter target cells that have been opsonized with immunoglobulin antibodies, they form conjugates, and either lyse or phagocytose the target cells, depending upon the effector cell type, the target cell type and the specific Fc receptor type (FcR) involved.

It has been demonstrated that target cell conjugation with an effector cell and lysis can also be induced by a covalently cross-linked bispecific heteroantibody made up of both anti-Fc receptor antibody and antibody directed against a target cell epitope. When effector cells bind such heteroaggregates to their Fc receptor, they can specifically bind and lyse target cells which have not been opsonized, but which express the appropriate target antigen (See e.g. U.S. Patent Application Serial No: 972,871; Karpovsky et al. (1984) *J. Exp. Med.* 160:1686-1701). Segal et al. have reported cytotoxicity of tumor cells by mouse monocytes with an attached heteroantibody which joins the Fc receptor of the monocyte on one end with tumor cell epitopes on the other end (See U.S. Patent No. 4,676,980). Recently, a variety of bispecific monoclonal antibodies and immunotoxins have been shown to confer antitumor effects *in vitro* as well *in vivo* (See e.g., World Patent No: 9208892; Pan et al (1990) *J. Immunol.*, 145:267-275; Trail et al. (1993) *Science (Washington, D.C.)*, 261:212-215; Weiner et al. (1993) *J. Immunol.*, 151:2877-2886; Link et al. (1993) *Blood*, 81:3343-3349; and Vallera, D.A. (1994) *Blood*, 83:309-317).

The binding of a heteroantibody to FcR is mediated by the Fc region of the antibody. This binding is ordinarily susceptible to inhibition by physiological concentrations of immunoglobulin. However, monoclonal antibodies, which bind to a site on the Fc receptor distinct from the binding site for endogenous immunoglobulin, have been produced (see, for example, Anderson et al., *J. Biol. Chem.* 261:12856 (1986); and Shen et al., *J. Immunol.* 137:3378-3382 (1986)). These antibodies are useful as the effector-specific moiety of heteroantibodies, because serum immunoglobulin does not interfere with targeted effector cell killing.

Methods for making novel antibodies to the Fc receptor or *in vivo* methods for testing the efficacy of an antibody for administration in humans would be useful.

- 2 -

5     **Summary of the Invention**

The present invention provides transgenic non-human animals expressing human Fc receptors (FcR), and methods for making and using the transgenic animals (e.g., to test anti-human FcR binding, generate high affinity antibodies etc.).

10     Accordingly, in one aspect, the invention features a non-human transgenic animal which expresses a human Fc receptor (FcR). The Fc receptor type can be human Fc $\gamma$  (e.g., Fc $\gamma$ RI, Fc $\gamma$ RII or Fc $\gamma$ RIII), Fc $\alpha$  (e.g., Fc $\alpha$ RI), or Fc $\epsilon$  (e.g., Fc $\epsilon$ RI or Fc $\epsilon$ RII). In one embodiment, expression of the human FcR is controlled by endogenous human regulatory sequences which naturally flank the FcR gene in humans, and which control expression patterns and levels of FcR.

15     Transgenic non-human animals (e.g., mammals) of the invention can be of a variety of species including murine (rodents (e.g., mice, rats), avian (chicken, turkey, fowl), bovine (beef, cow, cattle), ovine (lamb, sheep, goats), porcine (pig, swine), and piscine (fish). In a preferred embodiment, the transgenic animal is a rodent, such as a mouse or a rat.

20     In another aspect, the invention features methods for using non-human transgenic animals which express human Fc receptors. For example, the animals can be used as accurate animal models for studying human FcR function, such as anti-human FcR binding and FcR-mediated immune functions. Alternatively, the animals can be used to generate antibodies, such as anti-human FcR antibodies or antibodies specific for a particular antigen, or other immune reactions.

25     Accordingly, in one embodiment, the transgenic animals of the invention are used to test antibodies for binding to human FcR by administering the antibody to the transgenic non-human animal and then detecting (e.g., *in vitro* in a blood sample taken from the animal) antibody binding to FcR on FcR expressing cells. This method can be used, for example, to test the safety of an antibody (e.g., a humanized antibody) for *in vivo* clinical use.

30     In another embodiment, the transgenic animals are used to test the ability of anti-human FcR antibodies (e.g., monospecific, bispecific, tri-specific, multi-specific) to target molecules (e.g., antigens or cells) to Fc receptor expressing cells for e.g., killing or phagocytosis of the target molecule by the FcR expressing cell. For example, the animals can be used to test the ability of an anti-human Fc antibody, linked to or specific for an antigen, to target the antigen to an Fc receptor-bearing immune cell.

35     In yet another embodiment, the transgenic animals of the invention are used to detect the ability of an anti-human FcR antibody (e.g., mono-, bi-, tri- or multispecific) to generate an immune response as indicated by, for example, by an increase in the level of a cytokine or an antibody.

40

5 In still another embodiment, the transgenic animals are used to generate high affinity human antibodies specific for a particular antigen by coupling the antigen to an anti-human Fc receptor antibody to obtain a antibody antigen conjugate, immunizing the transgenic animal with the conjugate, and then selecting (e.g., isolating) an antibody specific to the antigen from e.g., a body sample taken from the animal. In one  
10 embodiment, the antigen is poorly immunogenic.

In yet another embodiment, the transgenic animals are used to generate high affinity human antibodies specific for a particular antigen (e.g., a poorly immunogenic antigen) by crossing the transgenic animal with a compatible non-human transgenic animal capable of making human antibodies, e.g., a mouse genetically engineered to  
15 express fully human antibodies, to generate a founder. The founder can then be administered an antigen to generate antibodies specific for the antigen.

Other features and advantages of the instant invention will become more apparent from the following detailed description and claims.

## 20 **Detailed Description of the Invention**

The present invention is based, in part, on the finding that microinjection of a nucleic acid encoding a human Fc receptor, e.g., Fc $\gamma$ RIa (CD64) or Fc $\alpha$ RI (CD89), under control of endogenous (e.g., human) regulatory sequences, into the pronucleus of fertilized mouse eggs produced founder mice expressing functional human Fc receptors  
25 on macrophages, monocytes and neutrophils, but not on other blood cells (e.g. lymphocytes). This expression pattern is similar to that found in humans. Moreover, it was found that the regulation of human FcR expression in transgenic mice was also similar to that in humans, and that the expressed human FcR was functionally competent (e.g., interacted with mouse signaling molecules). These results demonstrated the  
30 generation of non-human transgenic animals which were highly accurate models of human FcR receptor systems.

## **Definitions**

As used herein, the following terms and phrases shall have the meanings set forth  
35 below:

"Transgenic animal" is intended to include any non-human animal in which one or more of the cells of the animal contain heterologous nucleic acid encoding a human Fc receptor, that has been introduced by way of human intervention, such as by transgenic techniques well known in the art. The nucleic acid is introduced into the cell,  
40 directly or indirectly by introduction into a precursor of the cell, by way of deliberate genetic manipulation, such as by microinjection or by infection with a recombinant

- 4 -

5 virus. The term genetic manipulation does not include classical cross-breeding, or *in vitro* fertilization, but rather is directed to the introduction of a recombinant DNA molecule. This molecule may be integrated within a chromosome, or it may be extrachromosomally replicating DNA.

10 The term "non-human animals" is intended to include any vertebrate such as mammals; birds; reptiles; and amphibians. Suitable mammals include: rodent, non-human primates, sheep, dogs and cows. Suitable birds include chickens, geese, and turkeys. Preferred non-human animals are selected from the rodent family including rat and mouse, most preferably mouse.

15 As used herein, the term "transgenic cell" refers to a cell containing a transgene. As used herein, the term "transgene" means a nucleic acid sequence (encoding, e.g., a human Fc receptor), which is partly or entirely heterologous, i.e., foreign, to the transgenic animal or cell into which it is introduced, or, is homologous to an endogenous gene of the transgenic animal or cell into which it is introduced, but which is designed to be inserted, or is inserted, into the animal's genome in such a way as to alter the genome  
20 of the cell into which it is inserted (e.g., it is inserted at a location which differs from that of the natural gene or its insertion results in a knockout). A transgene can include one or more transcriptional regulatory sequences and any other nucleic acid, such as introns, that may be necessary for optimal expression of a selected nucleic acid.

The term "transgenic gene construct" comprises a nucleic acid molecule, e.g., a  
25 vector, containing the subject gene, e.g., the FcR gene, operably linked in a manner capable of replicating and expressing the gene in a host cell. The FcR gene construct can be introduced into a non-human animal cell by nucleic acid-mediated gene transfer. As used herein, the term "nucleic acid" refers to polynucleotides such as deoxyribonucleic acid (DNA), and, where appropriate, ribonucleic acid (RNA). The  
30 term should also be understood to include, as equivalents, analogs of either RNA or DNA made from nucleotide analogs, and, as applicable to the embodiment being described, single-stranded (such as sense or antisense) and double-stranded polynucleotides.

As used herein, the term "vector" refers to a nucleic acid molecule capable of  
35 transporting another nucleic acid to which it has been linked. One type of preferred vector is an episome, i.e., a nucleic acid capable of extra-chromosomal replication. Preferred vectors are those capable of autonomous replication and/expression of nucleic acids to which they are linked. Vectors capable of directing the expression of genes to which they are operatively linked are referred to herein as "expression vectors". In  
40 general, expression vectors of utility in recombinant DNA techniques are often in the form of "plasmids" which refer to circular double stranded DNA loops which, in their

- 5 -

5 vector form are not bound to the chromosome. In the present specification, "plasmid" and "vector" are used interchangeably as the plasmid is the most commonly used form of vector. However, the invention is intended to include such other forms of expression vectors which serve equivalent functions and which become known in the art subsequently hereto.

10 "Transcriptional regulatory sequence" is a generic term used throughout the specification to refer to DNA sequences, such as initiation signals, enhancers, and promoters, which induce or control transcription of protein coding sequences with which they are operably linked. In preferred embodiments, transcription of a recombinant FcR gene is under the control of a promoter sequence (or other transcriptional regulatory  
15 sequence) which controls the expression of the recombinant gene in a cell-type in which expression is intended. It will also be understood that the recombinant gene can be under the control of transcriptional regulatory sequences which are the same or which are different from those sequences which control transcription of a naturally-occurring form of FcR.

20 A "substantially pure" nucleic acid is a nucleic acid which is one or both of: not immediately contiguous with either one or both of the sequences, e.g., coding sequences, with which it is immediately contiguous (i.e., one at the 5' end and one at the 3' end) in the naturally-occurring genome of the organism from which the nucleic acid is derived; or which is substantially free of a nucleic acid sequence with which it occurs in the  
25 organism from which the nucleic acid is derived. The term includes, for example, a recombinant DNA which is incorporated into a vector, e.g., into an autonomously replicating plasmid or virus, or into the genomic DNA of a prokaryote or eukaryote, or which exists as a separate molecule (e.g., a cDNA or a genomic DNA fragment produced by polymerase chain reaction (PCR) or restriction endonuclease treatment)  
30 independent of other DNA sequences. Substantially pure DNA also includes a recombinant DNA which is part of a hybrid gene encoding additional Fc receptor sequences.

"Homology," or "sequence identity," as used herein, refers to the sequence similarity between two polypeptide molecules or between two nucleic acid molecules.  
35 When a position in both of the two compared sequences is occupied by the same base or amino acid monomer subunit, e.g., if a position in each of two DNA molecules is occupied by adenine, then the molecules are homologous or have sequence identity at that position. The percent of homology or sequence identity between two sequences is a function of the number of matching or homologous positions shared by the two  
40 sequences divided by the number of positions compared x 100. For example, if 6 of 10 of the positions in two sequences are matched or homologous then the two sequences are

- 6 -

5 60% homologous or have 60% sequence identity. By way of example, the DNA sequences ATTGCC and TATGGC share 50% homology or sequence identity. Generally, a comparison is made when two sequences are aligned to give maximum homology or sequence identity.

10 The terms "peptides," "proteins," and "polypeptides" are used interchangeably herein.

A transgene of the present invention causes cells of a non-human animal transformed with the transgene to express a recombinant form of an Fc receptor, e.g., a human Fc receptor (such as FcRI, FcRII or FcRIII) recognizing any antibody isotype (e.g.  $\alpha$ ,  $\gamma$  or  $\epsilon$ ). As used herein, the term "Fc receptor" or "FcR" includes a member of  
15 the family of Multi-chain Immune Recognition Receptors (MIRR), consisting of distinct ligand binding  $\alpha$ -chains, which non covalently associate with shared signaling components. The signaling molecules include FcR  $\gamma$ -,  $\beta$ - or  $\zeta$ - chains.

In preferred embodiments, the Fc receptor is a human Fc $\gamma$ R (e.g., Fc $\gamma$ RI, Fc $\gamma$ RII or Fc $\gamma$ RIII), Fc $\alpha$ RI, or Fc $\epsilon$ R (e.g., Fc $\epsilon$ RI or Fc $\epsilon$ RII).

20 In other preferred embodiments, the transgene expresses a human IgG receptor, e.g., an Fc-gamma receptor (Fc $\gamma$ R). As used herein, the term "IgG receptor" refers to any of the eight  $\gamma$ -chain genes located on chromosome 1. These genes encode a total of twelve transmembrane or soluble receptor isoforms which are grouped into three Fc $\gamma$  receptor classes: Fc $\gamma$ RI (CD64), Fc $\gamma$ RII (CD32), and Fc $\gamma$ RIII (CD16). In one preferred  
25 embodiment, the transgene expresses a human high affinity Fc $\gamma$ RI. The human Fc $\gamma$ RI is a 72 kDa molecule, which shows high affinity for monomeric IgG ( $10^8$  -  $10^9$  M $^{-1}$ ).

In still other preferred embodiments, the transgene expresses a human IgA receptor, e.g., an Fc-alpha receptor (Fc $\alpha$ R (CD89)). The term "IgA receptor" is intended to include the gene product of one  $\alpha$ -gene (Fc $\alpha$ RI) located on chromosome 19. This  
30 gene is known to encode several alternatively spliced transmembrane isoforms of 55 to 110 kDa. Fc $\alpha$ RI (CD89) is constitutively expressed on monocytes/macrophages, eosinophilic and neutrophilic granulocytes, but not on non-effector cell populations. Fc  $\alpha$ RI has medium affinity ( $\approx 5 \times 10^7$  M $^{-1}$ ) for both IgA1 and IgA2, which is increased upon exposure to cytokines such as G-CSF or GM-CSF (Morton, H.C. *et al.* (1996)  
35 *Critical Reviews in Immunology* 16:423-440).

In still other preferred embodiments, the transgene expresses a human IgE receptor, e.g., Fc $\epsilon$ RI or Fc $\epsilon$ RII (Ravetech, J.V. and J.P. Kinet (1991) *Annu. Rev. Immunol.* 9: 457). The nucleotide sequence of the  $\alpha$ - chain of Fc $\epsilon$ R are disclosed, e.g. in Shimizu, A. *et al.*, (1988) *Proc. Natl. Acad. Sci. USA* 85:1907-1911; Kinet, J.-P. *et al.*,  
40 (1987) *Biochemistry* 26:4605-4610; International Patent Application WO 89/05352.



- 7 -

5 In one preferred embodiment of the invention, the distribution of FcR, e.g., human FcR, expressed by the transgenic animal is similar to the distribution of the FcR in human cells. As used herein, the term "distribution" refers to the pattern of cell-type distribution. For example, human Fc $\alpha$ Rs are known to be present on monocytes, macrophages, neutrophils, and other myeloid cells. Fc $\alpha$ Rs are also known to be found  
10 on metamyelocytes, myelocytes, promyelocytes and some myeloblasts from, e.g., bone marrow.

Human Fc $\gamma$ RI is expressed in monocytes, macrophages, neutrophils and dendritic cells.

As used herein, the term "regulation" is intended to include any characteristic pattern of FcR gene expression in response to a signal, e.g., up- or downregulation of  
15 gene or protein expression on an effector cell by extracellular signals, e.g., humoral factors, e.g., cytokines; chemicals, e.g., vitamins. In preferred embodiments, the regulation of expression of the FcR transgene mirrors the regulation of expression of the endogenous receptor in a cell, e.g., a human cell. For example, expression of Fc $\alpha$ Rs can be increased by stimulation of myeloid cells. As an illustration, stimulation of U937  
20 cells and PLB985 cells with Phorbol Myristic Acetate (PMA) increases the cell surface level of Fc $\alpha$ R several folds (Maliszewski, et al. (1990) *J. Exp. Med.* 172:1665). Other agents which can increase the surface level of Fc $\alpha$ Rs include calcitriol, 1-25 dihydroxyvitamin D3, and tumor necrosis factor- $\alpha$  (TNF- $\alpha$ ). In other instances, the expression of Fc $\alpha$ R may not change in response to an extracellular signal, e.g., a  
25 cytokine, e.g., G-CSF.

In other examples, expression of Fc $\gamma$ RI has been found to be up-regulated by interferon gamma (IFN- $\gamma$ ) and G-CSF. This enhanced expression increases the cytotoxic activity of Fc $\gamma$ RI cells against targets.

In preferred embodiments, transgenically expressed human FcRs retain similar  
30 functional properties as are exhibited in human cells. For example, the transgenic FcR is preferably capable of mediating at least one Fc-receptor mediated effector cell function. The term "Fc-receptor mediated effector cell function" is intended to include any effector function, which is triggered by binding of immunoglobulin, e.g., IgA or IgG, to an Fc receptor on an effector cell. For example, binding of an immunoglobulin, e.g.,  
35 IgA or IgG, to cells bearing transgenically expressed human Fc $\alpha$ Rs or Fc $\gamma$ Rs can induce a variety of effector functions, such as phagocytosis, antibody dependent cellular cytotoxicity (ADCC), antigen presentation, inflammatory mediator release, lysozyme production, and superoxide anion production (Maliszewski, et al. (1990) *J. Exp. Med.* 172:1665). In other embodiments, the affinity of the transgenically expressed human  
40 FcRs may be modulated, e.g., enhanced or reduced, in response to an extracellular

- 8 -

5 signal, e.g., a cytokine, e.g., G-CSF or GM-CSF, in a similar fashion as an FcR in a human cell.

A "bispecific molecule" or "bispecific antibody" is intended to include a molecule, which minimally comprises a first binding determinant which recognizes an Fc receptor, e.g., an antibody or a fragment thereof that is capable of binding to an Fc  
10 receptor (FcR) on a effector cell; and a second binding determinant which recognizes a cell surface molecule on a target cell, e.g., a receptor, a cell surface antigen. Exemplary second binding determinants include an antibody, a fragment thereof, a genetic construct, or a ligand.

As used herein, the term "multispecific molecule" encompasses bispecific  
15 molecules, but also includes molecules having more than two binding determinants. For example, a multispecific molecule can include an "anti-enhancement factor (anti-EF) portion". The "anti-enhancement factor portion" can be an antibody, functional antibody fragment or a ligand that binds to a given molecule, e.g., an antigen or a receptor, and thereby results in an enhancement of the effect of the binding determinants for the F<sub>C</sub>  
20 receptor or target. The "anti-enhancement factor portion" can bind an F<sub>C</sub> receptor or a target.

In preferred embodiments, the antibody may be whole, i.e. having heavy and light chains or any fragment thereof, e.g., Fab or (Fab')<sub>2</sub> fragment. The antibody further may be a light chain or heavy chain dimer, or any minimal fragment thereof such as a Fv  
25 or a single chain construct as described in Ladner et al. U.S. Patent No. 4,946,778, issued August 7, 1990, the contents of which is expressly incorporated by reference. The term "monoclonal antibody" or "monoclonal antibody composition" as used herein refers to a preparation of antibody molecules of single molecular composition. A monoclonal antibody composition displays a single binding specificity and affinity for a  
30 particular epitope.

The term "antibody" as used herein is also intended to include chimeric, human, single chain and humanized antibodies, as well as binding fragments of such antibodies or modified versions of such antibodies. A "chimeric antibody" is intended to include an antibody in which the variable regions are from one species of animal and the  
35 constant regions are from another species of animal. For example, a chimeric antibody can be an antibody having variable regions which derive from a mouse monoclonal antibody and constant regions which are human. A "humanized antibody" or fragment includes any human antibody capable of retaining non-human hypervariable regions, also termed, the complementarity-determining regions (CDRs), for example, antibodies  
40 in which the CDRs are from one species of animal and the framework regions and constant regions of the antibody are from a different animal species. In a humanized

5 antibody, the CDRs can be from a mouse monoclonal antibody and the other regions of the antibody are human. In preferred embodiments, a human antibody is derived from known proteins NEWM and KOL for heavy chain variable regions (VHs) and REI for Ig kappa chain, variable regions (VKs).

10 In preferred embodiments, the anti-Fcγ receptor antibody is a human monoclonal antibody, the binding of which is not blocked by human immunoglobulin G (IgG). The production and characterization of these preferred monoclonal antibodies are described by Fanger et al. in PCT application WO 88/00052 and in U.S. Patent No. 4,954,617, the teachings of which are fully incorporated by reference herein. These antibodies bind to an epitope of FcγRI, FcγRII or FcγRIII at a site which is distinct from the Fcγ binding  
15 site of the receptor and, thus, their binding is not blocked substantially by physiological levels of IgG. Specific anti-FcγRI antibodies useful in this invention are mAb 22, mAb 32, mAb 44, mAb 62 and mAb 197. The hybridoma producing mAb 32 is available from the American Type Culture Collection, ATCC Accession No. HB9469. Anti-Fcγ RI mAb 22, F(ab')<sub>2</sub> fragments of mAb 22, and can be obtained from Medarex, Inc.  
20 (Annandale, N.J.). In other embodiments, the anti-Fcγ receptor antibody is a humanized form of monoclonal antibody 22. The humanized mab 22 antibody producing cell line was deposited at the American Type Culture Collection on November 4, 1992 under the designation HA022CL1 and has the accession no. CRL 11177.

In other embodiments, the anti-FcαR antibody is specific for an FcαR. Exemplary  
25 monoclonal antibodies include My 43, A77, A62, A59, and A3 (Monteiro et al. (1992) *J. Immunol.* 148:1764; Shen et al. (1989) *J. Immunol.* 143: 4117). Preferred anti-FcαR antibody are capable of binding to an FcαR without being inhibited by IgA. The antibody A77 has been produced by immunizing mice with acrylamide gel slices containing FcαR that was IgA affinity purified from human cell lysates. Monoclonal  
30 antibodies were screened according to three characteristics: staining of U937 cells at a higher density after PMA activation, selective reactivity with blood monocytes and granulocytes, and their ability to immunoprecipitate molecules of approximately 55 to 75 kDa from neutrophils and activated U937 cells.

In other embodiments, the ligand can be any ligand that interacts with a  
35 molecule. In a preferred embodiment, the ligand binds a protein, e.g., a surface protein on a target cell, such as a cancer cell. Preferred ligands include ligands to receptors, such as growth or differentiation factors. For example, a bispecific or multispecific molecule can comprise an epidermal growth factor, or at least a portion or modified form that is capable of interacting with a receptor, e.g., an epidermal growth factor  
40 receptor. In another preferred embodiment of the invention, the ligand is a small peptide, such as bombesin, gastrin-releasing peptide (GRP), litorin, neuromedin B, or

5 neuromedin C. The sequences of the peptides can be found, e.g., in U.S. Patent No. 5,217,955, the content of which is incorporated herein by reference. The ligand can also be a modified form of any of these peptides. The modification can increase binding to the receptor, decrease binding, or not affect the binding to a receptor. The modification of the ligand can also transform an agonist into an antagonist, such that the ligand inhibit  
10 rather than stimulate cell proliferation. The modification of the ligand can be an addition, a deletion, a substitution, or a modification of at least one amino acid.

The bispecific or multispecific molecules can be prepared by conjugating the anti-FcR and anti-target portions using methods known in the art. For example, a variety of coupling or cross-linking agents can be used for covalent conjugation.  
15 Examples of cross-linking agents include protein A, carbodiimide, N-succinimidyl-S-acetyl-thioacetate (SATA), N-succinimidyl-3-(2-pyridyldithio)propionate (SPDP), and sulfosuccinimidyl 4-(N-maleimidomethyl) cyclohexane-1-carboxylate (sulfo-SMCC) (see e.g., Karpovsky et al. (1984) *J. Exp. Med.* 160:1686; Liu, MA et al. (1985) *Proc. Natl. Acad. Sci. USA* 82:8648). Other methods include those described by Paulus  
20 (Behring Ins. Mitt. (1985) No. 78, 118-132); Brennan et al. (*Science* (1985) 229:81-83), and Glennie et al. (*J. Immunol.* (1987) 139: 2367-2375). Preferred conjugating agents are SATA and sulfo-SMCC, both available from Pierce Chemical Co. (Rockford, IL).

The bispecific molecule can also be a single chain bispecific molecule, such as a single chain bispecific antibody, a single chain bispecific molecule comprising one  
25 single chain antibody and a ligand, or a single chain bispecific molecule comprising two ligands. Multivalent molecules can also be single chain molecules or may comprise at least two single chain molecules. Methods for preparing bi- or multivalent antibodies are for example described in U.S. Patent Number 5,260,203; U.S. Patent Number 5,455,030; U.S. Patent Number 4,881,175; U.S. Patent Number 5,132,405; U.S. Patent  
30 Number 5,091,513; U.S. Patent Number 5,476,786; U.S. Patent Number 5,013,653; U.S. Patent Number 5,258,498; and U.S. Patent Number 5,482,858.

An "effector cell" refers to an immune cell which is involved in the effector phase of an immune response, as opposed to the cognitive and activation phases of an immune response. Exemplary immune cells include a cell of a myeloid or lymphoid  
35 origin, e.g., lymphocytes (e.g., B cells and T cells including cytolytic T cells (CTLs)), killer cells, natural killer cells, macrophages, monocytes, eosinophils, neutrophils, polymorphonuclear cells, granulocytes, mast cells, and basophils. Effector cells express specific Fc receptors and carry out specific immune functions. In preferred embodiments, an effector cell is capable of inducing antibody-dependent cellular  
40 toxicity (ADCC), e.g., a neutrophil capable of inducing ADCC. For example, monocytes, macrophages, neutrophils, eosinophils, and lymphocytes which express Fc $\alpha$

- 11 -

5 R are involved in specific killing of target cells and presenting antigens to other components of the immune system, or binding to cells that present antigens. In other embodiments, an effector cell can phagocytose a target antigen, target cell, or microorganism. The expression of a particular FcR on an effector cell can be regulated by humoral factors such as cytokines. For example, expression of FcγRI has been found  
10 to be up-regulated by interferon gamma (IFN-γ). This enhanced expression increases the cytotoxic activity of FcγRI-bearing cells against targets.

An "effector cell specific antibody" as used herein refers to an antibody or functional antibody fragment that binds the Fc receptor of effector cells. Preferred antibodies for use in the subject invention bind the Fc receptor of effector cells at a site  
15 which is not bound by endogenous immunoglobulin.

"Target cell" shall mean any undesirable cell in a subject (e.g., a human or animal) that can be targeted by a bi- or multispecific molecule. Examples of target cells include a cancer or a tumor cell, an antibody producing lymphocytes for treatment of an autoimmune disease, an IgE producing lymphocyte for treatment of an allergy, or a  
20 pathogen infected cell.

Exemplary cancer or tumor cells of the various organ systems include those malignant cells from the lung, breast, ovarian, lymphoid, gastrointestinal, head and neck, pancreas, liver, genito-urinary tract, kidney, colon cancers, rectum, renal-cell carcinoma, bone, blood, lymphatic system, prostate and/or testicular tumors, non-small cell  
25 carcinoma of the lung, cancer of the small intestine, central nervous system and cancer of the esophagus. Suitable targets among cancer cell antigens are preferably members of the human EGF-like receptor family, more preferably the cancer cell antigen is an EGF receptor, and most preferably the cancer cell antigen is HER-2/*neu*, HER-3, HER-4, or a heteromultimeric receptor comprised of at least one HER subunit. Additional preferred  
30 cancer cell antigens include carcinoembryonic antigen, gastrin releasing peptide receptor antigen, and TAG 72.

The term "carcinoma" is art recognized and refers to malignancies of epithelial or endocrine tissues including respiratory system carcinomas, gastrointestinal system carcinomas, genitourinary system carcinomas, testicular carcinomas, breast carcinomas,  
35 prostatic carcinomas, endocrine system carcinomas, and melanomas. Exemplary carcinomas include those forming from tissue of the cervix, lung, prostate, breast, head and neck, colon and ovary. The term also includes carcinosarcomas, e.g., which include malignant tumors composed of carcinomatous and sarcomatous tissues. An  
"adenocarcinoma" refers to a carcinoma derived from glandular tissue or in which the  
40 tumor cells form recognizable glandular structures. The term "sarcoma" is art recognized and refers to malignant tumors of mesenchymal derivation.

- 12 -

5           In certain embodiments, the cancer cell is from hematopoietic origin, e.g., arising from myeloid, lymphoid or erythroid lineages, or precursor cells thereof. Exemplary myeloid disorders include, but are not limited to, acute promyeloid leukemia (APML), acute myelogenous leukemia (AML) and chronic myelogenous leukemia (CML) (reviewed in Vaickus, L. (1991) *Crit Rev. in Oncol./Hematol.* 11:267-97). Lymphoid  
10 malignancies which may be treated by the subject method include, but are not limited to acute lymphoblastic leukemia (ALL) which includes B-lineage ALL and T-lineage ALL, chronic lymphocytic leukemia (CLL), prolymphocytic leukemia (PLL), hairy cell leukemia (HLL) and Waldenstrom's macroglobulinemia (WM). Additional forms of malignant lymphomas contemplated by the treatment method of the present invention  
15 include, but are not limited to non-Hodgkin lymphoma and variants thereof, peripheral T cell lymphomas, adult T cell leukemia/lymphoma (ATL), cutaneous T-cell lymphoma (CTCL), large granular lymphocytic leukemia (LGF) and Hodgkin's disease.

          The target can also be a pathogen, e.g., a microorganism, e.g., a virus, bacterium, fungus, protozoa, or a soluble antigen (such as rheumatoid factor or other auto-  
20 antibodies).

          Additionally, the target portion may comprise or be directed against an antigen. A preferred embodiment contains an antigen that can be used to induce a specific immune response against a chronic infection, against a tumor or cancer cell, or to deplete antigen in the circulation.

25           Transgenic animals of the present invention are highly accurate models of FcR expression and function in humans. Accordingly, these animals are useful in a number of different ways to study the mechanisms behind human FcR function and related events, and to generate and test products (e.g., antibodies, bispecifics, multispecifics etc.) useful in treating and diagnosing human diseases.

30           Accordingly, in one embodiment, the transgenic animals of the invention are used to test antibodies and multi- or bispecific molecules (e.g., for human safety and efficacy) for binding to target epitopes, such as a region of a human FcR, an antigen, or both. For example, the initiation of an immune response in the transgenic animal upon administration of such molecules indicates that the molecules will produce the same  
35 effect in humans. An immune response in a host can be detected for example by an increased level of a cytokine, production of an antibody or a T cell response. The transgenic animal can be engineered to contain target cells (e.g. tumor, virus) prior to administration of the multi- or bispecific molecule.

40           To detect antibody binding following administration of an anti-Fc antibody, or anti-Fc bi- or multispecific molecule to a transgenic animal, any suitable assay can be used. For example, a sample of the animals blood can be taken and assayed for the

5 presence of anti-Fc antibody-FcR complexes using screening assays known in the art, such as an enzyme-linked immunosorbent assay (ELISA), a radioimmunoassay (RIA), or a Western Blot Assay. Each of these assays generally detects the presence of protein-antibody complexes of particular interest by employing a labeled reagent (e.g., an antibody) specific for the complex of interest. Accordingly, in the present invention, 10 these assays are used to detect FcR-antibody complexes formed between immunoglobulins (e.g., IgG, IgA etc.) contained in the animal's blood serum and human FcR contained on the surface of particular cells in the animal.

The FcR-antibody complexes can be detected using e.g., an enzyme-linked antibody or antibody fragment which recognizes and specifically binds to the antibody- 15 FcR complexes. Alternatively, the complexes can be detected using any of a variety of other immunoassays. For example, the antibody can be radioactively labeled and used in a radioimmunoassay (RIA) (see, for example, Weintraub, B., Principles of Radioimmunoassays, Seventh Training Course on Radioligand Assay Techniques, The Endocrine Society, March, 1986, which is incorporated by reference herein). The 20 radioactive isotope can be detected by such means as the use of a  $\gamma$  counter or a scintillation counter or by autoradiography.

To detect an immune response following administration of an anti-Fc antibody, or anti-Fc bi- or multispecific molecule to a transgenic animal, any suitable procedure for measuring a change in the concentration of e.g., a cytokine, antibody or T cell 25 population in the plasma or serum of the animal can be used. For example, a change in a cytokine concentration *in vivo* can be detected via a variety of immunoassays, such as enzyme immunoassay (EIA) or radioimmunoassay (RIA). Exemplary cytokines that can be assayed include: granulocyte/macrophage colony stimulating factor (GM-CSF), granulocyte colony-stimulating factor (G-CSF), macrophage colony-stimulating factor 30 (M-CSF), interleukins 1 -12 (IL-1 to IL-12).

For example, plasma can be obtained from a transgenic animal to which an antibody, bispecific, or multispecific molecule has been administered. The concentration of a cytokine can be measured using an EIA by detecting the interaction of the cytokine with an antibody, which is in turn conjugated to an enzyme. The activity of 35 the enzyme is detected by the reaction with an appropriate substrate, preferably a chromogenic substrate, in such a manner as to produce a chemical moiety which can be detected, for example, by spectrophotometric, fluorimetric or by visual means (Voller, "The Enzyme Linked Immunosorbent Assay (ELISA)", Diagnostic Horizons 2:1-7, 1978, Microbiological Associates Quarterly Publication, Walkersville, MD; Voller, et 40 al., J. Clin. Pathol. 31:507-520 (1978); Butler, Meth. Enzymol. 73:482-523 (1981); Maggio, (ed.) Enzyme Immunoassay, CRC Press, Boca Raton, FL, 1980; Ishikawa, et

5 al., (eds.) Enzyme Immunoassay, Kaku Shoin, Tokyo, 1981). Enzymes which can be used to detectably label the antibody include, but are not limited to, malate dehydrogenase, staphylococcal nuclease, delta-5-steroid isomerase, yeast alcohol dehydrogenase, alpha-glycerophosphate dehydrogenase, triose phosphate isomerase, horseradish peroxidase, alkaline phosphatase, asparaginase, glucose oxidase, beta-  
10 galactosidase, ribonuclease, urease, catalase, glucose-6-phosphate dehydrogenase, glucoamylase and acetylcholinesterase. The detection can be accomplished by colorimetric methods which employ a chromogenic substrate for the enzyme. Detection may also be accomplished by visual comparison of the extent of enzymatic reaction of a substrate in comparison with similarly prepared standards.

15 Detection of a cytokine may also be accomplished using a radioimmunoassay (RIA) (see, for example, Weintraub, B., Principles of Radioimmunoassays, Seventh Training Course on Radioligand Assay Techniques, The Endocrine Society, March, 1986, which is incorporated by reference herein). The radioactive isotope can be detected by such means as the use of a  $\gamma$  counter or a scintillation counter or by  
20 autoradiography.

It is also possible to label the anti-cytokine antibody with a fluorescent compound. When the fluorescently labeled antibody is exposed to light of the proper wave length, its presence can then be detected. Among the most commonly used fluorescent labeling compounds are fluorescein isothiocyanate, rhodamine,  
25 phycoerythrin, phycocyanin, allophycocyanin, o-phthaldehyde and fluorescamine. The antibody can also be detectably labeled using fluorescence emitting metals such as  $^{152}\text{Eu}$ , or others of the lanthanide series. These metals can be attached to the antibody using such metal chelating groups as diethylenetriaminepentaacetic acid (DTPA) or ethylenediaminetetraacetic acid (EDTA). The antibody also can be detectably labeled  
30 by coupling it to a chemiluminescent compound. The presence of the chemiluminescent-tagged antibody is then determined by detecting luminescence that arises during the course of a chemical reaction. Examples of particularly useful chemiluminescent labeling compounds are luminol, isoluminol, thionin, acridinium ester, imidazole, acridinium salt and oxalate ester. Likewise, a bioluminescent  
35 compound may be used to label the antibody. Bioluminescence is a type of chemiluminescence found in biological systems in, which a catalytic protein increases the efficiency of the chemiluminescent reaction. The presence of a bioluminescent protein is determined by detecting the presence of luminescence. Important bioluminescent compounds for purposes of labeling are luciferin, luciferase and  
40 aequorin.



- 15 -

5 A non-human transgenic animal of the present invention expressing a human Fc  
receptor can further provide an indication of the safety of a particular humanized  
antibody for administration to a human. For example, a humanized antibody can be  
administered to the transgenic animal and the binding of the antibody to the human Fc  
10 receptor expressed by the animal can be detected as an indication that the humanized  
antibody is safe (i.e. will not elicit an immune response) for *in vivo* human use.

As used herein, the term "administration," is intended to include any route of  
introducing a composition, e.g., a humanized antibody, into a subject. Examples of  
routes of administration which can be used include injection (subcutaneous, intravenous,  
parenterally, intraperitoneally, intrathecal, etc.), oral, inhalation, rectal and transdermal.  
15 The pharmaceutical preparations are of course given by forms suitable for each  
administration route. For example, these preparations are administered in tablets or  
capsule form, by injection, inhalation, eye lotion, ointment, suppository, etc.  
administration by injection, infusion or inhalation; topical by lotion or ointment; and  
rectal by suppositories. Oral administration is preferred. The injection can be bolus or  
20 can be continuous infusion. Depending on the route of administration, the composition  
can be coated with or disposed in a selected material to protect it from natural conditions  
which may detrimentally effect its ability to perform its intended function. The  
composition can be administered alone, or in conjunction with either another agent as  
described above or with a pharmaceutically acceptable carrier, or both. The compound  
25 can be administered prior to the administration of the other agent, simultaneously with  
the agent, or after the administration of the agent.

The phrases "parenteral administration" and "administered parenterally" as used  
herein means modes of administration other than enteral and topical administration,  
usually by injection, and includes, without limitation, intravenous, intramuscular,  
30 intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal,  
intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticular, subcapsular,  
subarachnoid, intraspinal and intrasternal injection and infusion. The phrases "systemic  
administration," "administered systemically", "peripheral administration" and  
"administered peripherally" as used herein mean the administration of a composition,  
35 such that it enters the subject's system and, thus, is subject to metabolism and other like  
processes, for example, subcutaneous administration.

An antibody, bispecific or multispecific molecule can be administered to a  
subject (e.g., transgenic animal) in the form of a pharmaceutical composition in  
conjunction with a pharmaceutically acceptable carrier. As used herein, the phrase  
40 "pharmaceutically acceptable carrier" is intended to include substances that can be

- 16 -

- 5 coadministered with a multispecific molecule and allows the molecule to perform its intended function.

Pharmaceutical compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. In all cases, the composition must be sterile and must be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, asorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, polyalcohols such as manitol, sorbitol, sodium chloride in the composition. Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate and gelatin.

25 Sterile injectable solutions can be prepared by incorporating the multispecific molecule in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the active compound into a sterile vehicle which contains a basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and freeze-drying which yields a powder of the active ingredient (e.g., antibody) plus any additional desired ingredient from a previously sterile-filtered solution thereof.

The transgenic animals expressing human Fc receptors as described herein can also be used to generate high affinity human antibodies particularly to poorly immunogenic antigens. For example, an antigen can be coupled to an anti-Fc receptor antibody to obtain an antibody antigen conjugate. A variety of coupling or cross-linking agents can be found above in the description of the preparation of bispecific molecules which can be used for covalent conjugation of an anti-Fc receptor antibody to obtain an antibody antigen conjugate. The conjugate can then be used to immunize a non-human

- 17 -

- 5 transgenic animal expressing a human Fc receptor. Antibodies specific to the antigen can then be selected using known techniques.

Methods for immunizing a non-human transgenic animal are known in the art. (See, for example, *Antibodies: A Laboratory Manual* ed. by Harlow and Lane (Cold Spring Harbor Press: 1988)). For example, a non-human transgenic animal, such as a  
10 transgenic mouse, can be immunized with an immunogenic form of a protein or a peptide, e.g., antibody antigen conjugate. Techniques for conferring immunogenicity on a protein or peptide include conjugation to carriers or other techniques known in the art. An antibody antigen conjugate can be administered in the presence of adjuvant. The progress of immunization can be monitored by detection of antibody titers in plasma or  
15 serum. Standard ELISA or other immunoassays can be used with the immunogen as antigen to assess the levels of antibodies.

High affinity human antibodies can alternatively be generated by crossing a non-human transgenic animal expressing a human Fc receptor with a compatible (i.e. an animal of the same species but opposite sex) non-human transgenic animal capable of  
20 making human antibodies (e.g. as described in Bruggeman et. al., (1993) *Year Immunol* 7:33-40; Tuaillon et. al., (1993) *PNAS* 90:3720-3724; Bruggeman et. al., (1991) *Eur. J. Immunol.* 21:1323-1326 and Wood et. al., WO 91/00906) to generate a founder and administering an antigen to the founder to generate novel antibodies.

In addition, the transgenic animals described herein can be used to assess the role  
25 of Fc receptors in mucosal immunity and allergic processes.

### **Transgenic Animals**

Detailed methods for generating non-human transgenic animal are described herein and in the section entitled "Examples" below. Transgenic gene constructs can be  
30 introduced into the germ line of an animal to make a transgenic mammal. For example, one or several copies of the construct may be incorporated into the genome of a mammalian embryo by standard transgenic techniques.

Any non-human animal can be used in the methods described herein. Preferred mammals are rodents, e.g., rats or mice.

35 In an exemplary embodiment, the "transgenic non-human animals" of the invention are produced by introducing transgenes into the germline of the non-human animal. Embryonal target cells at various developmental stages can be used to introduce transgenes. Different methods are used depending on the stage of development of the embryonal target cell. The specific line(s) of any animal used to practice this invention  
40 are selected for general good health, good embryo yields, good pronuclear visibility in

5 the embryo, and good reproductive fitness. In addition, the haplotype is a significant factor.

Introduction of the transgene into the embryo can be accomplished by any means known in the art such as, for example, microinjection, electroporation, or lipofection. For example, the Fc receptor transgene can be introduced into a mammal by  
10 microinjection of the construct into the pronuclei of the fertilized mammalian egg(s) to cause one or more copies of the construct to be retained in the cells of the developing mammal(s). Following introduction of the transgene construct into the fertilized egg, the egg may be incubated *in vitro* for varying amounts of time, or reimplanted into the surrogate host, or both. *In vitro* incubation to maturity is within the scope of this  
15 invention. One common method is to incubate the embryos *in vitro* for about 1-7 days, depending on the species, and then reimplant them into the surrogate host.

The progeny of the transgenically manipulated embryos can be tested for the presence of the construct by Southern blot analysis of the segment of tissue. If one or more copies of the exogenous cloned construct remains stably integrated into the  
20 genome of such transgenic embryos, it is possible to establish permanent transgenic mammal lines carrying the transgenically added construct.

The litters of transgenically altered mammals can be assayed after birth for the incorporation of the construct into the genome of the offspring. Preferably, this assay is accomplished by hybridizing a probe corresponding to the DNA sequence coding for the  
25 desired recombinant protein product or a segment thereof onto chromosomal material from the progeny. Those mammalian progeny found to contain at least one copy of the construct in their genome are grown to maturity.

For the purposes of this invention a zygote is essentially the formation of a diploid cell which is capable of developing into a complete organism. Generally, the  
30 zygote will be comprised of an egg containing a nucleus formed, either naturally or artificially, by the fusion of two haploid nuclei from a gamete or gametes. Thus, the gamete nuclei must be ones which are naturally compatible, i.e., ones which result in a viable zygote capable of undergoing differentiation and developing into a functioning organism. Generally, a euploid zygote is preferred. If an aneuploid zygote is obtained,  
35 then the number of chromosomes should not vary by more than one with respect to the euploid number of the organism from which either gamete originated.

In addition to similar biological considerations, physical ones also govern the amount (e.g., volume) of exogenous genetic material which can be added to the nucleus of the zygote or to the genetic material which forms a part of the zygote nucleus. If no  
40 genetic material is removed, then the amount of exogenous genetic material which can be added is limited by the amount which will be absorbed without being physically

- 19 -

5 disruptive. Generally, the volume of exogenous genetic material inserted will not  
exceed about 10 picoliters. The physical effects of addition must not be so great as to  
physically destroy the viability of the zygote. The biological limit of the number and  
variety of DNA sequences will vary depending upon the particular zygote and functions  
10 because the genetic material, including the exogenous genetic material, of the resulting  
zygote must be biologically capable of initiating and maintaining the differentiation and  
development of the zygote into a functional organism.

The number of copies of the transgene constructs which are added to the zygote  
is dependent upon the total amount of exogenous genetic material added and will be the  
15 amount which enables the genetic transformation to occur. Theoretically only one copy  
is required; however, generally, numerous copies are utilized, for example, 1,000-20,000  
copies of the transgene construct, in order to insure that one copy is functional. As  
regards the present invention, there will often be an advantage to having more than one  
functioning copy of each of the inserted exogenous DNA sequences to enhance the  
20 phenotypic expression of the exogenous DNA sequences.

Any technique which allows for the addition of the exogenous genetic material  
into nucleic genetic material can be utilized so long as it is not destructive to the cell,  
nuclear membrane or other existing cellular or genetic structures. The exogenous  
genetic material is preferentially inserted into the nucleic genetic material by  
25 microinjection. Microinjection of cells and cellular structures is known and is used in  
the art.

Reimplantation is accomplished using standard methods. Usually, the surrogate  
host is anesthetized, and the embryos are inserted into the oviduct. The number of  
embryos implanted into a particular host will vary by species, but will usually be  
30 comparable to the number of off spring the species naturally produces.

Transgenic offspring of the surrogate host may be screened for the presence  
and/or expression of the transgene by any suitable method. Screening is often  
accomplished by Southern blot or Northern blot analysis, using a probe that is  
complementary to at least a portion of the transgene. Western blot analysis using an  
35 antibody against the protein encoded by the transgene may be employed as an alternative  
or additional method for screening for the presence of the transgene product. Typically,  
DNA is prepared from tail tissue and analyzed by Southern analysis or PCR for the  
transgene. Alternatively, the tissues or cells believed to express the transgene at the  
highest levels are tested for the presence and expression of the transgene using Southern  
40 analysis or PCR, although any tissues or cell types may be used for this analysis.

5           Alternative or additional methods for evaluating the presence of the transgene include, without limitation, suitable biochemical assays such as enzyme and/or immunological assays, histological stains for particular marker or enzyme activities, flow cytometric analysis, and the like. Analysis of the blood may also be useful to  
10           detect the presence of the transgene product in the blood, as well as to evaluate the effect of the transgene on the levels of various types of blood cells and other blood constituents.

          Progeny of the transgenic animals may be obtained by mating the transgenic animal with a suitable partner, or by *in vitro* fertilization of eggs and/or sperm obtained from the transgenic animal. Where mating with a partner is to be performed, the partner  
15           may or may not be transgenic and/or a knockout; where it is transgenic, it may contain the same or a different transgene, or both. Alternatively, the partner may be a parental line. Where *in vitro* fertilization is used, the fertilized embryo may be implanted into a surrogate host or incubated *in vitro*, or both. Using either method, the progeny may be evaluated for the presence of the transgene using methods described above, or other  
20           appropriate methods.

          The transgenic animals produced in accordance with the present invention will include exogenous genetic material. As set out above, the exogenous genetic material will, in certain embodiments, be a DNA sequence which results in the production of an Fc receptor. Further, in such embodiments the sequence will be attached to a  
25           transcriptional control element, e.g., a promoter, which preferably allows the expression of the transgene product in a specific type of cell.

          Retroviral infection can also be used to introduce transgene into a non-human animal. The developing non-human embryo can be cultured *in vitro* to the blastocyst stage. During this time, the blastomeres can be targets for retroviral infection (Jaenich,  
30           R. (1976) *PNAS* 73:1260-1264). Efficient infection of the blastomeres is obtained by enzymatic treatment to remove the zona pellucida (*Manipulating the Mouse Embryo*, Hogan eds. (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, 1986). The viral vector system used to introduce the transgene is typically a replication-defective retrovirus carrying the transgene (Jahner et al. (1985) *PNAS* 82:6927-6931; Van der Putten et al. (1985) *PNAS* 82:6148-6152). Transfection is easily and efficiently obtained  
35           by culturing the blastomeres on a monolayer of virus-producing cells (Van der Putten, *supra*; Stewart et al. (1987) *EMBO J.* 6:383-388). Alternatively, infection can be performed at a later stage. Virus or virus-producing cells can be injected into the blastocoele (Jahner et al. (1982) *Nature* 298:623-628). Most of the founders will be  
40           mosaic for the transgene since incorporation occurs only in a subset of the cells which formed the transgenic non-human animal. Further, the founder may contain various

5 retroviral insertions of the transgene at different positions in the genome which generally will segregate in the offspring. In addition, it is also possible to introduce transgenes into the germ line by intrauterine retroviral infection of the midgestation embryo (Jahner et al. (1982) *supra*).

10 A third type of target cell for transgene introduction is the embryonal stem cell (ES). ES cells are obtained from pre-implantation embryos cultured *in vitro* and fused with embryos (Evans et al. (1981) *Nature* 292:154-156; Bradley et al. (1984) *Nature* 309:255-258; Gossler et al. (1986) *PNAS* 83: 9065-9069; and Robertson et al. (1986) *Nature* 322:445-448). Transgenes can be efficiently introduced into the ES cells by DNA transfection or by retrovirus-mediated transduction. Such transformed ES cells  
15 can thereafter be combined with blastocysts from a non-human animal. The ES cells thereafter colonize the embryo and contribute to the germ line of the resulting chimeric animal. For review see Jaenisch, R. (1988) *Science* 240:1468-1474.

#### DNA Constructs

20 The Fc receptors can be expressed from a construct which includes regulatory sequences specific for the receptor, e.g., an human FcR promoter, e.g., a human Fc $\gamma$ R promoter, e.g., a human Fc $\alpha$ R promoter, and a nucleic acid encoding the FcR, e.g., human Fc $\gamma$ R or human Fc $\alpha$ R. Preferably, these regulatory sequences are genomic in origin, and include one or more introns. For example, the transgenic construct can  
25 include regulatory regions located in the 5'-flanking regions of a gene encoding FcR, e.g., an Fc $\gamma$ R or an Fc $\alpha$ R, operably linked to the FcR coding sequences in a manner capable of replicating and expressing the gene in a host cell. If additional flanking sequence are useful in optimizing expression, such sequences can be cloned using the existing sequences as probes. Additional sequences necessary for maximizing  
30 processing of the transgene can be derived from either cDNA or genomic sequences.

The gene organization of the human FcRs has been described (Tepler, I. et al. (1989) *J. Biol. Chem.* 264: 5912-15; J. van de Winkel et al. (1991), *J. Biol. Chem.* 266 (20): 13449-455; de Wit et al. (1995) *J. Immunol.* 155: 1204-1209). For example, the gene encoding the prototypic human Fc $\alpha$ RI (CD89) consists of five exons and four  
35 introns that span approximately 12 kilobase pairs: a leader peptide which is encoded by two exons, the second of which is 36 bp long and specifies the predicted peptidase cleavage site; the third and fourth exons which code for two homologous Ig-like domains; and a final exon which encodes a short extracellular region, a hydrophobic transmembrane region, and a short cytoplasmic tail. The 5'- flanking region for the  
40 human Fc $\alpha$ RI has also been mapped, as well as the transcription initiation sites (de Wit et al. (1995) *J. Immunol.* 155: 1204-1209).

- 22 -

5           An expression system or construct described herein can also include a 3' untranslated region downstream of the DNA sequence. Such regions can stabilize the RNA transcript of the expression system and thus increases the yield of desired protein from the expression system. Among the 3' untranslated regions useful in the constructs of this invention are sequences that provide a poly A signal. Such sequences may be  
10       derived, e.g., from the SV40 small t antigen, the Fc receptor untranslated region or other 3' untranslated sequences well known in the art. Preferably, the 3' untranslated region is derived from an Fc receptor. The length of the 3' untranslated region is not critical but the stabilizing effect of its poly A transcript appears important in stabilizing the RNA of the expression sequence.

15           Optionally, the expression system or construct includes a 5' untranslated region between the promoter and the DNA sequence encoding the signal sequence. Such untranslated regions can be from the same control region from which promoter is taken or can be from a different gene, e.g., they may be derived from other synthetic, semi-synthetic or natural sources. Again their specific length is not critical, however, they  
20       appear to be useful in improving the level of expression.

          Expression systems can be prepared using methods known in the art. An expression system can be prepared as part of a larger plasmid. Such preparation allows the cloning and selection of the correct constructions in an efficient manner as is known in the art. Expression systems can be located between convenient restriction sites on the  
25       plasmid so that they can be easily isolated from the remaining plasmid sequences for incorporation into the desired mammal.

          The various methods employed in the preparation of the plasmids and transformation of host organisms are known in the art. For other suitable expression systems for both prokaryotic and eukaryotic cells, as well as general recombinant  
30       procedures, see *Molecular Cloning A Laboratory Manual*, 2nd Ed., ed. by Sambrook, Fritsch and Maniatis (Cold Spring Harbor Laboratory Press: 1989) Chapters 16 and 17.

          The transgenic animals of the present invention can be used as accurate animal models for studying human FcR function, such as anti-human FcR binding and FcR-mediated immune functions. Alternatively, the animals can be used to generate  
35       antibodies, such as anti-human FcR antibodies or antibodies specific for a particular antigen, or other immune reactions.

          For example, the transgenic animals can be used to generate high affinity human antibodies specific for a particular antigen (e.g., a poorly immunogenic antigen) by crossing the transgenic animal with a compatible non-human transgenic animal capable  
40       of making human antibodies, e.g., a mouse genetically engineered to express fully



5 human antibodies. Such crossing generates a founder to which an antigen can be administered to generate antibodies specific for the antigen.

In an illustrative embodiment, mice genetically engineered to express fully human antibodies after immunization (referred to herein as "HuMab mice") can be generated by inactivating the genes coding for mouse antibodies, as described, for  
10 example, in U.S. Patent No. 5,434,340 and U.S. Patent No. 5,591,669, the disclosures of which are hereby incorporated by reference herein. Inactivation of mouse antibodies can be achieved by generating a 'double-knockout mouse' in which the endogenous immunoglobulin heavy chain and the  $\kappa$ -light chain genes are disrupted by targeted deletion of the exons coding for the constant regions ( $C\mu$  and  $JC\kappa$ ). Separate transgenes  
15 can be constructed which contain both the human immunoglobulin heavy chain genes and the human  $\kappa$  light chain genes. In humans, these genes encompass about 1-2 megabases each, a size which is too large to isolate intact. The essential regions can be assembled in condensed form in so-called 'miniloci'. The heavy chain minilocus contains 2-6  $V_H$  gene segments, 15  $D_H$  and 6  $J_H$  gene segments, and the  $S\mu$  and  $C\mu$  and  
20  $S\gamma$  and  $C\gamma$  gene segments. The  $\kappa$ -light chain minilocus contains 1-17  $V\kappa$ -gene segments, 5  $J\kappa$  and the  $C\kappa$  gene segments (Lonberg, N. *et al.* (1994) *Nature* 368: 856-859; Tuailon, N. *et al.* (1993) *Proc. Natl. Acad. Sci. USA* 90: 3720-3724). These miniloci can be subsequently incorporated into the genome of the 'double-knockout' mice. Several consecutive versions of these double-knockout/double transgenic HuMab  
25 mice can be generated, which incorporate increasing amounts of the human heavy- and light-chain loci. For example, HuMab mice have been generated which incorporate a 100 kb heavy chain transgene containing six V segments, and a 200 kb  $\kappa$  light chain transgene containing 17  $V\kappa$ -segments. These HuMab mice can be immunized using conventional immunization protocols, and have been shown to efficiently generate high-  
30 affinity human IgG1 antibodies against a broad panel of antigens (Fishwild, D.M. *et al.* (1996) *Nature Biotech* 14: 845-851; Lonberg, N. and D. Huszar (1995) *Int. Rev. Immunol.* 13: 65-93). The antibodies generated following these protocols have been shown to have excellent biological activity, and long serum half-lives.

HuMab mice generated as described above can be crossed with the transgenic  
35 animals of the present invention, e.g., human  $Fc\gamma RI$  transgenic mice (e.g., the line 1852 described in Example 2). Targeting a given antigen to cells expressing human  $Fc\gamma RI$  in the transgenic animal can provide for a very effective method of triggering antibody responses to the antigen. In one embodiment, the immunogenicity of the antigen can be enhanced by producing a fusion protein of the antigen with an antibody against an Fc  
40 receptor, e.g., an antibody against a human Fc receptor such as human  $Fc\gamma RI$  or human  $Fc\alpha R$ . For example, a C-terminal fusion of the antigen with the heavy chain of an

- 24 -

5 antibody against human FcγRI, e.g., humanized H22 antibody, can be administered to a human FcγRI transgenic mice. The fusion protein then targets the antigen to human FcγRI-expressing cells in the transgenic animal, thus triggering highly effective antibody responses to the antigen.

10 The present invention is further illustrated by the following examples which should not be construed as limiting in any way. The contents of all cited references (including literature references, issued patents, published patent applications, and co-pending patent applications) cited throughout this application are hereby expressly incorporated by reference.

## 15 EXAMPLES

### Example I: Generation of Human FcγRI-Transgenic Mice

To generate human FcγRIa transgenic mice, a genetic construct coding for the human FcγRIa (CD64) was microinjected into the pronucleus of fertilized mouse eggs.  
20 The construct was a 18 kB genomic fragment (phage 1) containing endogenous human regulatory sequences, cloned from human leukocyte DNA using the method of Van de Winkel, J.G.J., L.K. Ernst, C.L. Anderson and I. M. Chiu, *J. Biol. Chem.* (1991) 266:13449-13455. The nucleotide sequence of the 5'-flanking region of the construct is provided by Van de Winkel, *supra.*, including the sequences containing the transcription  
25 initiation sites responsible for constitutive and inducible transcription of the FcγRIa gene. The 18 kB fragment was cloned into pTZ18 plasmid (Pharmacia), released from the vector by restriction endonuclease digestion, and purified by agarose gel electrophoresis and electroelution.

The gene organization of FcγRIa consists of five introns and six exons and spans  
30 9.4 kb pairs: the leader sequence is encoded by two exons, the second of which is 21 base pairs long and contains the predicted site of the peptidase cleavage; the third, fourth, and fifth exons, each encode homologous Ig-like extracellular domains; the hydrophobic transmembrane region and a highly charged cytoplasmic tail are encoded by a final exon (Van de Winkel, *supra.*).

35 The final DNA concentration was adjusted to 4 μg/ml. Fertilized mouse eggs were recovered in cumulus from the oviducts of superovulated FVB/N females that had mated with males several hours earlier. The DNA fragments were injected into the most accessible pronucleus of each fertilized egg using the method of Van Lohuizen. M., S. Verbeek, P. Krimpenfort, J. Domen, C. Saris, T. Radaszkiewicz and A. Berns, *Cell*  
40 (1989) 56:673-682. After overnight culturing, 2-cell stage embryos were implanted into the oviducts of day 1 pseudopregnant foster animals and carried to term. Several weeks

- 25 -

5 after birth of animals that had developed from microinjected eggs, total genomic DNA was prepared from tail biopsies using the method of Hogan, B.L.M., F. Constantini and E. Lacy, Cold Spring Harbor, New York: Cold Spring Harbor Laboratory (1986).

This DNA was digested with HindIII enzyme, separated on agarose gels, blotted and probed with human FcγRI cDNA p135 (Allen, J.M. and B. Seed, *Science* (1989)  
10 243:378-380). Two positive founders were identified, coded 1852 and 1853.

#### Example II: Characterization of Human FcγRI-Transgenic Mice

Two independent transgenic lines were generated, and in both lines human FcγRI was highly expressed on peritoneal macrophages, and at lower levels on monocytes.  
15 One line (1852) also expressed low levels of human FcγRI on neutrophils, which was not observed in line 1853. All other blood cells (e.g. lymphocytes) were negative for human FcγRI-expression.

Incubation of mouse cells with Interferon-γ or Interleukin-10 showed enhanced expression of human FcγRI on monocytes/macrophages, while Interleukin-4 down-regulated human FcγRI-expression. These cytokines showed similar effects on huFcγRI  
20 upon injection *in vivo*. In addition, injection of Granulocyte Colony Stimulating Factor (G-CSF) triggered increased expression of human FcγRI *in vivo*, but not *in vitro*.

Overall, these results showed the human FcγRI molecule to be expressed in exactly the same types of cells in both transgenic mice and humans (i.e., similar  
25 distribution patterns of FcγRI in transgenic mice and humans). In addition, the regulation of receptor expression in transgenic mice was similar to that in humans. Thus, the correct endogenous human regulatory elements were both present and functional in transgenic mice, making these transgenic models very accurate and valuable indicators of the human system.

30 In addition, it was shown that human FcγRI expressed in transgenic mice was functionally competent and interacted with mouse signaling molecules (e.g., FcR γ chain). Specifically, the human FcγRI molecule was shown to bind its physiological ligand (i.e., FITC-conjugated human IgG). Functional studies using bispecific antibodies targeting human FcγRI specifically showed human FcγRI to be active in both  
35 phagocytosis and antibody dependent cellular cytotoxicity (ADCC) as described below. In particular, a M22 x anti-Her-2/*neu* bispecific antibody was tested for ADCC of Her-2/*neu*-targeted human SK-BR3 cells. The bispecific antibody M22 x anti-Her-2/*neu* which contains Fab' gamma fragments of anti-FcγRI antibody (monoclonal antibody 22) crosslinked to an Fab fragment of anti-Her-2/*neu* monoclonal antibody (520C9) was  
40 prepared using the method of Glennie, M.J. et al. (1987) *J. Immunol.* 139:2367. A

- 26 -

- 5 bispecific antibody M22 x anti-ox red blood cell (RBC) Fab antibody (described in Anderson *et al.* (1991) *J. Exp. Med.*) was additionally tested for ADCC.

Macrophages expressing human Fc $\gamma$ RI in transgenic mice showed a decrease in mouse Fc $\gamma$  receptors (measured by monoclonal antibody 2.4G2) which can be explained by competition for receptor signaling subunits (e.g. Fc $\gamma$  chain). Injection of human Fc $\gamma$ RI transgenic mice with humanized anti-Fc $\gamma$ RI antibody (monoclonal 22) triggered a  
10 very rapid mouse anti-human antibody response. More importantly, most antibodies were of the IgG (and not the IgM type), which demonstrated that antigen uptake via huFc $\gamma$ RI is highly effective.

In conclusion, the studies described herein demonstrate that transgenic mice  
15 expressing human Fc $\gamma$ RI are accurate models for studying human Fc $\gamma$ RI function *in vivo*.

### Example III: Generation of Human Fc $\alpha$ RI-Transgenic Mice

To generate human Fc $\alpha$ RI transgenic mice, a genetic construct coding for the human Fc $\alpha$ RI (CD89) receptor was microinjected into the pronucleus of fertilized  
20 mouse eggs. The genetic construct was a 37 Kb genomic fragment (cosmid clone R31931) cloned from human chromosome 19 as described by Ashworth, L.K., Batzer, M.A. et al., *Natural Genetics* (1995) 11:422-427. The fragment contained endogenous regulatory sequences and was released from the vector by *Sfi*I restriction endonuclease digestion.

25 The gene encoding human Fc $\alpha$ R (CD89) consists of five exons and four introns that span approximately 12 kilobase pairs: a leader peptide which is encoded by two exons, the second of which is 36 bp long and specifies the predicted peptidase cleavage site; the third and fourth exons which code for two homologous Ig-like domains; and a final exon which encodes a short extracellular region, a hydrophobic transmembrane  
30 region, and a short cytoplasmic tail. The 5'-flanking region for the human Fc $\alpha$ RI have also been mapped, along with the transcription initiation sites (de Wit et al. (1995) *J. Immunol.* 155: 1204-1209).

To prepare transgenic mice, a final DNA concentration was adjusted to 4  $\mu$ g/ml. Fertilized mouse eggs were recovered in cumulus from the oviducts of  
35 superovulated FVB/N females that had mated with males several hours earlier. The DNA fragments were injected into the most accessible pronucleus of each fertilized egg using the methods of Van Lohuizen, M., S. Verbeek, P. Krimpenfort, J. Domen. C. Saris, T. Radaszkiewicz and A. Berns, *Cell* (1989) 56:673-682. After overnight culturing, 2-cell stage embryos were implanted into the oviducts of day 1  
40 pseudopregnant foster animals and carried to term. Several weeks after birth of animals that had developed from microinjected eggs, total genomic DNA was prepared from tail

- 27 -

5 biopsies using the methods of Hogan, B.L.M., F. Constantini and E. Lacy, Cold Spring Harbor, New York: Cold Spring Harbor Laboratory (1986).

To identify transgenic mice, genomic DNA was prepared from tail biopsies, digested with EcoRI enzyme, separated on agarose gel, blotted and probed with human Fc $\alpha$ RI cDNA as described in Maliszewski, C.R., March, C.J. et al., *J. Exp. Med.* (1990)  
10 172:16-65. Three positive founders were obtained, referred to as 2106, 2107 and 2126.

**Example IV:** Characterization of the Human Fc $\alpha$ RI-Transgenic Mice

Two independent transgenic lines were generated using founders 2107 and 2126. Expression of human Fc $\alpha$ RI was high on neutrophils, moderate on monocytes and  
15 negative on lymphocytes. Thus, the human Fc $\alpha$ RI expression pattern in these transgenic lines was similar to expression of Fc $\alpha$ RI on human cells, which show constitutive expression of Fc $\alpha$ RI on monocytes, macrophages, eosinophilic and neutrophilic granulocytes (Morton, H.C. (1996) *Critical Reviews in Immunology* 16:423-440). Transgenic line 2126 showed a higher expression of human Fc $\alpha$ RI on neutrophils than  
20 line 2107. In addition, injection of Granulocyte Colony Stimulating Factor (G-CSF) did not increase expression of human Fc $\alpha$ RI *in vivo*, mirroring the regulation of Fc $\alpha$ R in response to G-CSF on human cells.

Overall, these results demonstrate that the regulatory elements of the human Fc $\alpha$  RI were both present and functionally active in the transgenic mice, as evidenced by  
25 e.g., similarities in the cellular distribution patterns and regulation of human Fc $\alpha$ RI between the transgenic mice and humans. Thus, transgenic mice expressing human Fc $\alpha$  RI of the present invention provide highly accurate models for human systems.

**Example V:** Functional Characterization of Human Fc $\alpha$ RI-Transgene

30 Functional studies showed the transgenically expressed human Fc $\alpha$ RI to be active in both phagocytosis of yeast (*Candida albicans*) by neutrophils using the bispecific antibody A77 x anti-*Candida*. The A77 antibody is described in Monteiro et al. (1992) *J. Immunol.* 148:1764. In addition, these studies showed the transgenically expressed human Fc $\alpha$ RI to be active in antibody dependent cellular cytotoxicity  
35 (ADCC) using the bispecific antibody A77 x anti-Her-2/*neu* to target human SK-BR3 cells. The protocols describing these functional studies are described below. These results demonstrate that human Fc $\alpha$ RI receptors expressed in transgenic mice were functionally competent in mediating, for example, phagocytosis of yeast cells and cytotoxic activity, providing further accuracy as models for studying the mechanism of  
40 Fc $\alpha$ RI receptors *in vivo*.

- 28 -

5 *Candida Phagocytosis Assays*

*Candida albicans* (strain ATCC 448585) was cultured overnight at 37°C in Sabouraud Maltose Broth (Difco, Detroit, MI), harvested by centrifugation, washed three times in PBS, and labeled by incubation with FITC (Sigma, St. Louis, MO) at a concentration of 0.1 mg/mL in 0.1 mol/L NaH<sub>2</sub>PO<sub>4</sub>/Na<sub>2</sub>HPO<sub>4</sub> buffer (pH 9.6) for 30 minutes at 4°C.

10 After three washed with PBS, 5 × 10<sup>5</sup> yeast particles were incubated for 30 minutes at 37°C with 2 × 10<sup>5</sup> isolated PMN without or with 10 µg/mL [A77 × α *Candida*] bispecific antibody. *Candida albicans* phagocytosis was quantitated by measuring FITC-fluorescence intensities of cells on a flow cytometer using PE-conjugated CD11b MoAb (Becton Dickinson, San Jose, CA) as a gate marker for PMN. Alternatively, phagocytes

15 was determined in cytopsin preparations evaluated by microscopy.

*Antibody Dependent Cellular Cytotoxicity Assays*

Target cells were labelled with 200 µCi for 2 hours. Whole blood, isolated effector cells (50 µL), sensitizing antibodies 0.4 µg/mL, for bispecific antibody anti-Fcα antibody x anti-Her-2/*neu* (A77 Fab x 520C9 Fab) and RF10<sup>+</sup> were added into round-bottom microtiter plates. Assays were started by adding target cell suspensions (50 µL), giving a final volume of 200 µL, and an effector to target cell ratio of 80:1 with isolated cells. After 3 hours at 37°C, assays were stopped by centrifugation, and Cr release from triplicate was measured.

25

Percentage of cellular cytotoxicity was calculated using the formula:

$$\% \text{ specific lysis} = \frac{\text{experimental cpm} - \text{basal cpm}}{\text{maximum release} - \text{basal cpm}} \times 100$$

30

**Equivalents**

Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents of the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims.

35

**5     Claims**

1.     A non-human transgenic animal which expresses a human Fc receptor.
2.     The non-human transgenic animal of claim 1, wherein the human Fc receptor is  
10     selected from the group consisting of FcγRI, FcγRII and FcγRIII.
3.     The non-human transgenic animal of claim 1, wherein the Fc receptor is selected  
from the group consisting of FcεRI and FcεRII.
- 15     4.     A non-human transgenic animal which expresses a human FcγRI receptor.
5.     A non-human transgenic animal which expresses a human Fcα receptor.
6.     The non-human transgenic animal of claim 5, wherein the human Fcα receptor is  
20     FcαRI.
7.     The non-human transgenic animal of claim 4, wherein the distribution of said  
human FcγRI receptor expression is similar to that in humans.
- 25     8.     The non-human transgenic animal of claim 5, wherein the distribution of said  
human Fcα receptor expression is similar to that in humans.
9.     A non-human transgenic animal which expresses a human FcγRI receptor,  
wherein the distribution and regulation of said human FcγRI receptor expression is  
30     similar to that in humans.
10.     A non-human transgenic animal which expresses a human Fcα receptor, wherein  
the distribution and regulation of said human Fcα receptor expression is similar to that  
in humans.  
35
11.     A nonhuman transgenic animal which expresses a human Fc receptor under the  
control of human regulatory sequences.
12.     The non-human transgenic animal of claim 1, wherein the transgenic animal is a  
40     mammal.

- 30 -

- 5     13.     The non-human transgenic animal of claim 1, wherein the transgenic animal is a rodent.
14.     The non-human transgenic animal of claim 1, wherein the transgenic animal is a mouse.
- 10     15.     A method for testing an *in vivo* utility of a bispecific molecule comprising,
- administering a bispecific molecule into a non-human transgenic animal expressing a human Fc receptor; and
- 15     detecting an immune response as an indication of the *in vivo* utility.
16.     The method of claim 15, wherein the step of detecting comprises detecting an increased level of a cytokine or the production of an antibody.
- 20     17.     A method for testing binding of an antibody to the human Fc receptor comprising:
- administering the antibody to a non-human transgenic animal expressing a human Fc receptor; and
- 25     detecting binding of the antibody to the human Fc receptor expressed by the non-human transgenic animal.
18.     A method for making a high affinity antibody specific for an antigen comprising:
- 30     coupling an antigen to an anti-human Fc receptor antibody to obtain a antibody antigen conjugate;
- immunizing a non-human transgenic animal expressing a human Fc receptor with the conjugate; and
- 35     selecting an antibody specific to the antigen.
19.     The method of claim 18, wherein the antigen is poorly immunogenic.
- 40



- 31 -

- 5     20.     A method for making a high affinity human antibody specific for an antigen comprising:

10               crossing a non-human transgenic animal expressing a human Fc  
                 receptor with a compatible non-human transgenic animal capable of  
                 making human antibodies to generate a founder; and

                 administering an antigen to the founder to generate human antibodies  
                 specific for the antigen.

- 15     21.     The method of claim 20, wherein the antigen is poorly immunogenic.



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>C12N 15/00, 15/13, A01K 67/027,</b> <b>C07K 14/705</b>	<b>A3</b>	<b>(11) International Publication Number:</b> <b>WO 99/00010</b> <b>(43) International Publication Date:</b> 7 January 1999 (07.01.99)
<b>(21) International Application Number:</b> PCT/US98/13171 <b>(22) International Filing Date:</b> 25 June 1998 (25.06.98)  <b>(30) Priority Data:</b> 08/884,541 27 June 1997 (27.06.97) US  <b>(71) Applicant:</b> MEDAREX, INC. [US/US]; 1545 Route 22 East, P.O. Box 953, Annandale, NJ 08801-0953 (US).  <b>(72) Inventor:</b> VAN DE WINKEL, J., G., J.; Werdorperwaard 1A, NL-3984 PR Odijk (NL).  <b>(74) Agents:</b> REMILLARD, Jane, E. et al.; Lahive & Cockfield, LLP, 28 State Street, Boston, MA 02109 (US).		<b>(81) Designated States:</b> AU, CA, JP, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).  <b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the</i> <i>claims and to be republished in the event of the receipt of</i> <i>amendments.</i>  <b>(88) Date of publication of the international search report:</b> 15 April 1999 (15.04.99)
<b>(54) Title:</b> TRANSGENIC ANIMALS EXPRESSING HUMAN Fc RECEPTORS  <b>(57) Abstract</b>  Transgenic animals expressing Fc receptors and uses for the animals in testing the efficacy of human antibodies and in generating novel antibodies are described.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/US 98/13171

**A. CLASSIFICATION OF SUBJECT MATTER**  
IPC 6 C12N15/00 C12N15/13 A01K67/027 C07K14/705

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)  
IPC 6 A01K C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	HEIJNEN, I.A.F.M. ET AL.: "Antigen targeting to myeloid-specific human Fc-gamma-RI-CD64 triggers enhanced antibody responses in transgenic mice cd" JOURNAL OF CLINICAL INVESTIGATION, vol. 97, no. 2, January 1996, pages 331-338, XP002081335 see the whole document	1,4,7,9, 11-19
X,P	GUYRE, P.M. ET AL.: "Increased potency Fc-receptor-targeted antigens" CANCER IMMUNOLOGY IMMUNOTHERAPY, vol. 45, no. 3-4, 1997, XP002081336 see the whole document	1,4,7,9
O,X	& 5th World Conference on Bispecific Antibodies, 25-28 June 1997, Volendam, NL	1

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

\* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

29 January 1999

Date of mailing of the international search report

23 02 99

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Chambonnet, F

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 98/13171

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 95 28959 A (SLOAN KETTERING INST CANCER ;RAVETCH JEFFREY V (US); TAKAI TOSHIYU) 2 November 1995 see page 145, line 1 - page 158, line 12 ---	1,2, 12-14
X	FLAMAND, V. ET AL.: "Delayed maturation of CD4-CD8-Fc-Gamma-RII-III+ T and natural killer cell precursors in Fc-Epsilon-RI-Gamma transgenic mice" JOURNAL OF EXPERIMENTAL MEDICINE, vol. 184, no. 5, November 1996, pages 1725-1735, XP002091634 see the whole document ---	1,3,12, 14
X	SCHARENBERG, A. M. ET AL.: "the FcRbeta subunit functions as an amplifier of Fc Rgamma mediated cell activation signal" THE JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, vol. 99, no. 1 part 2, January 1997, page s406 XP002091635 see Abstract 1651 see the whole document ---	1,3
X	WO 95 15376 A (US GOVERNMENT) 8 June 1995  see page 24, line 32 - page 30, line 7; claims -----	1,3, 12-15

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US 98/13171

## Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☒ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

### Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☒ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1 4 7 9 and partially 2 11-21

A non-human transgenic animal which expresses a human Fc-gamma-RI receptor

2. Claims: partially 2 11-21

A non-human transgenic animal which expresses a human Fc-gamma-RII receptor

3. Claims: partially 2 11-21

A non-human transgenic animal which expresses a human Fc-gamma-RIII receptor

4. Claims: 3 and partially 11-21

A non-human transgenic animal which expresses a human Fc-epsilon receptor

5. Claims: 5 6 8 10 and partially 11-21

A non-human transgenic animal which expresses a human Fc-alpha receptor

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 98/13171

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9528959 A	02-11-1995	AU 2461995 A	16-11-1995
WO 9515376 A	08-06-1995	AU 1213695 A	19-06-1995